Jane Huang Acquires Shares in Protara Therapeutics, Inc.

Jane Huang recently acquired 31,000 shares of Protara Therapeutics, Inc. (NasdaqGM: TARA) on June 15, 2026. The shares were bought at an unspecified price, and this transaction was not part of a planned trading program.

Insider Buying and Selling at Protara Therapeutics, Inc.

On June 15, 2026, several insiders, including Jane Huang, each purchased 31,000 shares of Protara Therapeutics. The transactions were not part of any pre-arranged trading plans and involved insiders like Barry Flannelly, Richard Levy, Michael Edward Solomon, Roger Garceau, and Cynthia Smith.

Other Institutional Activity in Protara Therapeutics

Institutional investors have also been active in Protara Therapeutics. Janus Henderson Group PLC increased its holdings by 65,395 shares, reaching 5,207,011 shares valued at approximately $27.2 million. BlackRock, Inc. significantly boosted its position by 986,100 shares, bringing its total to 3,394,968 shares worth about $17.7 million. Millennium Management LLC made a notable addition of 2,077,906 shares, ending with 2,831,208 shares valued at $14.8 million.

Protara Therapeutics Stock Snapshot

Shares of Protara Therapeutics, Inc. are trading around $3.94. The company has a market capitalization of approximately $214.1 million and a beta of 1.452, indicating its volatility compared to the market. Over the past year, the stock has ranged from $2.77 to $7.82. The 50-day moving average is $4.87, while the 200-day moving average stands at $5.26. The company maintains a strong current ratio of 15.69 and a quick ratio of 15.39, with a debt-to-equity ratio of 1.69.

Analysts Set New Price Targets

Analysts continue to show optimism for Protara Therapeutics. On May 20, 2026, Oppenheimer maintained a 'buy' rating with a price target of $28.00. Similarly, JP Morgan reaffirmed its 'buy' rating on May 14, 2026, with a target of $26.00. HC Wainwright & Co. also maintained a 'buy' rating with a $27.00 target on April 29, 2026. The consensus among seven analysts is a 'buy' recommendation, with a mean target price of $26.57.

About Protara Therapeutics

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, NY. The company focuses on developing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is in Phase II clinical trials for non-muscle invasive bladder cancer and lymphatic malformations. Additionally, Protara is working on an investigational therapy for patients receiving parenteral nutrition. The company is led by CEO Jesse Shefferman and employs 46 people.

Bottom Line

Jane Huang's purchase of Protara Therapeutics shares reflects an insider's interest in the company's potential. While 13F filings and insider transactions provide insights, they are backward-looking and may not represent current positions. Investors track these moves for potential signals about the company's future prospects.